INAVA promotes aggressiveness of papillary thyroid cancer by upregulating MMP9 expression

BACKGROUND: Innate immunity activator (INAVA) has been shown to be elevated in lung adenocarcinoma. However, its expression pattern and function in papillary thyroid cancer (PTC) are unknown. This study aimed to identify the clinical, biological, and mechanistic impacts of INAVA on PTC. METHODS: Usi...

Descripción completa

Detalles Bibliográficos
Autores principales: Guan, Hongyu, Guo, Yan, Liu, Liehua, Ye, Runyi, Liang, Weiwei, Li, Hai, Xiao, Haipeng, Li, Yanbing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887255/
https://www.ncbi.nlm.nih.gov/pubmed/29632659
http://dx.doi.org/10.1186/s13578-018-0224-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887255/
https://www.ncbi.nlm.nih.gov/pubmed/29632659
http://dx.doi.org/10.1186/s13578-018-0224-4

Ejemplares similares